Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients

The objective of this study was to identify the prognostic factors and to propose a new risk model in metastatic castration-resistant prostate cancer (mCRPC) patients. The clinical data were retrospectively obtained for 102 mCRPC patients who received cancer treatment between 2005 and 2018 at the Un...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2023-02, Vol.13 (1), p.2672-2672, Article 2672
Main Authors: Hakozaki, Yuji, Yamada, Yuta, Takeshima, Yuta, Taguchi, Satoru, Kawai, Taketo, Nakamura, Masaki, Iwaki, Takuya, Teshima, Taro, Kinoshita, Yoshitaka, Akiyama, Yoshiyuki, Sato, Yusuke, Yamada, Daisuke, Suzuki, Motofumi, Kume, Haruki
Format: Article
Language:English
Subjects:
692/4025
692/4028
Aged
Androgen Antagonists - therapeutic use
Castration
Decision making
Hemoglobin
Humanities and Social Sciences
Humans
Kinetics
Lymph nodes
Male
Medical prognosis
Metastases
Metastasis
multidisciplinary
Multivariate analysis
Patients
Prognosis
Prostate cancer
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant - drug therapy
Retrospective Studies
Risk groups
Science
Science (multidisciplinary)
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this study was to identify the prognostic factors and to propose a new risk model in metastatic castration-resistant prostate cancer (mCRPC) patients. The clinical data were retrospectively obtained for 102 mCRPC patients who received cancer treatment between 2005 and 2018 at the University of Tokyo Hospital. We investigated clinical and pathological parameters, including prostate-specific antigen (PSA) kinetic profiles under androgen deprivation treatment, and identified predictors of overall survival (OS). The median age and PSA were 73 (Interquartile range [IQR], 68–79) years and 5.00 (IQR, 2.77–13.6) ng/ml. The median follow-up was 34 (IQR, 17–56) months. In univariate analysis, ‘lymph node metastasis’, ‘Hemoglobin (Hb)’, ‘Time to nadir PSA (TNPSA)’, ‘PSA doubling time (PSADT)’, ‘Time to CRPC’, and ‘presence of pain’ were prognostic factors. Multivariate analysis identified ‘Hb 
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-023-29634-5